- Home
- CANF vs HLN Comparison
CANF vs HLN Comparison
Compare CANF & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- HLN
- Stock Information
- Founded
- CANF 1994
- HLN 2022
- Country
- CANF Israel
- HLN United Kingdom
- Employees
- CANF N/A
- HLN N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- HLN Package Goods/Cosmetics
- Sector
- CANF Health Care
- HLN Consumer Discretionary
- Exchange
- CANF Nasdaq
- HLN Nasdaq
- Market Cap
- CANF 7.9M
- HLN 45.6B
- IPO Year
- CANF N/A
- HLN N/A
- Fundamental
- Price
- CANF $1.09
- HLN $10.25
- Analyst Decision
- CANF Strong Buy
- HLN Buy
- Analyst Count
- CANF 2
- HLN 1
- Target Price
- CANF $14.00
- HLN $10.95
- AVG Volume (30 Days)
- CANF 422.0K
- HLN 15.3M
- Earning Date
- CANF 05-13-2025
- HLN 02-27-2025
- Dividend Yield
- CANF N/A
- HLN 1.64%
- EPS Growth
- CANF N/A
- HLN 38.94
- EPS
- CANF N/A
- HLN 0.20
- Revenue
- CANF $674,000.00
- HLN $14,062,871,660.00
- Revenue This Year
- CANF $461.72
- HLN $4.78
- Revenue Next Year
- CANF N/A
- HLN $4.75
- P/E Ratio
- CANF N/A
- HLN $25.28
- Revenue Growth
- CANF N/A
- HLN N/A
- 52 Week Low
- CANF $1.22
- HLN $8.12
- 52 Week High
- CANF $4.69
- HLN $10.80
- Technical
- Relative Strength Index (RSI)
- CANF 34.28
- HLN 53.63
- Support Level
- CANF $1.13
- HLN $10.15
- Resistance Level
- CANF $1.19
- HLN $10.34
- Average True Range (ATR)
- CANF 0.11
- HLN 0.19
- MACD
- CANF -0.02
- HLN 0.03
- Stochastic Oscillator
- CANF 1.35
- HLN 80.15
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About HLN Haleon plc (Each representing two)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.